BR112022015457A2 - Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido - Google Patents

Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido

Info

Publication number
BR112022015457A2
BR112022015457A2 BR112022015457A BR112022015457A BR112022015457A2 BR 112022015457 A2 BR112022015457 A2 BR 112022015457A2 BR 112022015457 A BR112022015457 A BR 112022015457A BR 112022015457 A BR112022015457 A BR 112022015457A BR 112022015457 A2 BR112022015457 A2 BR 112022015457A2
Authority
BR
Brazil
Prior art keywords
formulation
pill
making
heart failure
tablet
Prior art date
Application number
BR112022015457A
Other languages
English (en)
Portuguese (pt)
Inventor
Bi Mingda
Kiang Yuan-Hon
Lou Hao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112022015457A2 publication Critical patent/BR112022015457A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
BR112022015457A 2020-02-10 2021-02-10 Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido BR112022015457A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972506P 2020-02-10 2020-02-10
PCT/US2021/017429 WO2021163172A1 (en) 2020-02-10 2021-02-10 Omecamtiv mecarbil tablet

Publications (1)

Publication Number Publication Date
BR112022015457A2 true BR112022015457A2 (pt) 2022-10-04

Family

ID=74858801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015457A BR112022015457A2 (pt) 2020-02-10 2021-02-10 Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido

Country Status (9)

Country Link
US (1) US20230090391A1 (enExample)
EP (1) EP4103159A1 (enExample)
JP (1) JP7696353B2 (enExample)
CN (1) CN115279349A (enExample)
AU (1) AU2021221106A1 (enExample)
BR (1) BR112022015457A2 (enExample)
CA (1) CA3168513A1 (enExample)
IL (1) IL295490A (enExample)
WO (1) WO2021163172A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808321A (en) * 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
JP6634368B2 (ja) 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法

Also Published As

Publication number Publication date
CA3168513A1 (en) 2021-08-19
WO2021163172A1 (en) 2021-08-19
US20230090391A1 (en) 2023-03-23
JP7696353B2 (ja) 2025-06-20
JP2023513249A (ja) 2023-03-30
CN115279349A (zh) 2022-11-01
EP4103159A1 (en) 2022-12-21
IL295490A (en) 2022-10-01
AU2021221106A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
WO2020051207A3 (en) Aryl hydrocarbon receptor antagonists and methods of use
MX2023008854A (es) Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
BR112018011376A2 (pt) composição farmacêutica que compreende um inibi-dor de urat1 potente
MX2019006345A (es) Proceso para preparar microcapsulas de tamaño controlado que comprenden una etapa de fotopolimerizacion.
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
BR112012026953A8 (pt) Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica
BRPI0512583B8 (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções
AR064875A1 (es) Composiciones de tableta en tableta
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
BRPI0704238A (pt) preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica
EP3398948A3 (en) 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
BRPI0821644A2 (pt) Compostos derivados de benzimidazol carboxila ou hidroxila substituídos, processo para a sua preparação, composições farmacêuticas que os contêm, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por agonistas fxr e usos dos compostos
MX390461B (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
BR112018074660A2 (pt) composição para os cuidados pessoais, método para a redução do aparecimento de linhas finas, rugas, poros e/ou manchas de imperfeição e utilização de uma composição
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
BR112023018095A2 (pt) Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo
BR112016027674A2 (pt) Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
PY1903392A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso único diario
BR112022009361A2 (pt) Novas lactonas funcionalizadas como moduladores do receptor 7 de 5- hidroxitriptamina e seu método de uso
BR112019003912A2 (pt) composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo
BR112015014957A2 (pt) derivados de fluoroergolina e usos dos mesmos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]